In a world where innovation dictates the future, Alfaleus Technology Pvt. Ltd. (Alfaleus Tech) stands out as a disruptor in eye care diagnostics. Founded in 2018 by Sandal Kotawala—then a 23-year-old engineering undergraduate from Tamil Nadu, India—Alfaleus Tech set out to transform vision testing through Virtual Reality (VR) and state-of-the-art design.
Traditionally, the development cycle for medical devices is long and heavily regulated. This often keeps device manufacturers locked into decade-old technologies, despite rapid advances in areas like VR. Sensing this gap, Alfaleus Tech harnessed VR’s potential to precisely simulate and measure visual stimuli in a controlled environment—an approach that was nearly unthinkable just a decade ago.
From Concept to Commercialization
• First Breakthrough: In February 2019, Alfaleus Tech launched C3FA, the world’s first VR-based visual field perimeter, in collaboration with Remidio. This venture proved that VR could be leveraged for clinical diagnostics in ophthalmology.
• Next-Gen Development: Building on lessons from C3FA, the company introduced IVA (Intelligent Vision Analyser). With advanced design and improved accuracy, IVA made visual field testing portable, cost-effective, and more accessible to clinicians worldwide.
Clinical Collaborations & Support
Alfaleus Tech worked closely with leading hospitals and research institutes such as Aravind Eye Care (Pondicherry) to refine its products. Meanwhile, government and industry bodies like Startup India, BIRAC, DST, MeitY, and Invest India offered vital support, paving the way for robust product validation and eventual market adoption.
Impact & Global Reach
Today, over 250 ophthalmologists spanning India, Nigeria, Kenya, Nepal, and other countries rely on Alfaleus Tech’s solutions. More than 50,000 lives have already been touched by the company’s devices. Alfaleus Tech’s findings appear in top-tier forums like the All India Ophthalmological Society (AIOS), Glaucoma Society of India (GSI), Indian Neuro-Ophthalmic Conference, Journal of Glaucoma, and the Association for Research in Vision and Ophthalmology—underscoring its commitment to scientific rigor and knowledge-sharing.
Why This Innovation Matters
The Aegis Graham Bell Awards, inspired by one of history’s most iconic inventors, recognize visionaries who break barriers in technology. Alfaleus Tech embodies this spirit by championing next-gen healthcare. Its VR-based diagnostics go beyond incremental improvements, delivering a paradigm shift in how clinicians detect and manage vision disorders. What sets the company apart is its dedication to affordability and portability—ensuring medical professionals in even the most resource-constrained settings can access cutting-edge eye care tools.
Shaping the Future
By blending clinical insight, immersive technology, and user-focused design, Alfaleus Tech is at the forefront of medical innovation. Their journey exemplifies what the Aegis Graham Bell Awards celebrate: a relentless pursuit of groundbreaking solutions that bridge technology and human welfare. Moving forward, Alfaleus Tech envisions scaling their VR capabilities to address additional diagnostic challenges. Each milestone affirms their core philosophy—healthcare should be efficient, inclusive, and continuously evolving. In a rapidly transforming world, companies like Alfaleus Tech light the path toward a clearer, healthier future for all.
